12-O-retinoylphorbol-13-acetate

Also Known As:

12-ORPA; phorbol-12-retinoate-13-acetate; Retinoic acid, 9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa(3,4)benz(1,2-e)azulen-9-yl ester, (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9beta,9aalpha))-

Networked: 7 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Diterpenes: 1470
      - Phorbols: 26
        Phorbol Esters: 2726
        12-O-retinoylphorbol-13-acetate: 7

Related Diseases

1.	Neoplasms (Cancer) 04/01/1983 - "By means of a two-stage promotion protocol in mouse epidermis with 12-O-tetradecanoylphorbol-13-acetate as first-stage promoter and 12-O-retinoylphorbol-13-acetate as second-stage promoter, the effects of the former that are critical and obligatory for tumor promotion were shown to be irreversible in nature for at least 8 weeks. " 05/01/1988 - "Hyperplasiogenic and tumor-promoting phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate or 12-O-retinoylphorbol-13-acetate induce the sequential transient expression of the proto-oncogenes c-fos and c-myc and the ornithine decarboxylase gene in mouse skin in vivo. " 02/01/1988 - "This phenomenon is induced by other diterpene esters, such as 4-O-methyl TPA, 12-O-ethacrynylphorbol-13-acetate (EPA), 12-O-retinoylphorbol-13-acetate (RPA) and mezerein, which exert either convertogenic or promoting effects in skin tumor development in vivo. " 07/01/1987 - "Chronic treatment with the tumor-promoting phorbol esters 12-O-tetradecanoylphorbol-13-acetate (TPA) and 12-O-retinoylphorbol-13-acetate (RPA) causes permanently increased levels of active collagenolytic enzymes in the dermis and leads to a stable reduction of dermal collagen content. " 03/01/1987 - "During chronic treatment with the tumor promoting phorbol esters 12-O-tetradecanoylphorbol-13-acetate (TPA) and 12-O-retinoylphorbol-13-acetate (RPA) increased protein synthesis was observed that did not occur during treatment with the non-promoting mitogens 4-O-methyl-TPA and Ca-ionophore A 23187. "
2.	Carcinogenesis 11/01/1993 - "The induction of chromosome and/or genome mutations during the first steps of skin carcinogenesis was followed in male NMRI mice, treated with a 'two-stage' [9,10-dimethyl-1,2-benzanthracene (DMBA) + phorbol-12-myristate-13-acetate (TPA)], or a 'three-stage' [DMBA+methyl methanesulphonate (MMS) + phorbol-12-retinoate-13-acetate (RPA)] protocol. "
3.	Chromosome Aberrations (Chromosome Abnormalities) 04/01/1989 - "A dose of 100 mumol MMS was found to be almost as clastogenic as 10 nmol of the convertogenic tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), whereas the non-convertogenic promoter 12-O-retinoylphorbol-13-acetate (RPA, 10 nmol) did not induce chromosomal aberrations in vivo. "

Related Drugs and Biologics

1.	Phorbol Esters
2.	Proteins (Proteins, Gene)
3.	Ornithine Decarboxylase (Decarboxylase, Ornithine)
4.	Mitogens
5.	Ionophores
6.	Esters
7.	Enzymes
8.	Diterpenes
9.	Collagen
10.	Carcinogens

HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Application Error

An application error has occurred and our support engineers have been notified.

Please use the browser "Back" button and try your operation again.

OR if the error persists and you require an email response
please contact us at "cs at curehunter.com":

Your request
The circumstances of the error
Your login id/nickname or email

Return to Top Page